Arkolith/Insider Trading/XFOR/Form 4

Baldry Mark

Chief Commercial OfficerX4 Pharmaceuticals, Inc (XFOR) · full profile →Form 4 · filed Feb 14, 2025
Net Buying
Open-Market Buys
$19K
Open-Market Sells
$0
Net Open-Market Flow
$19K
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 12, 2025Grant(A)600K—$0729K
Nov 15, 2024Buy(P)13K$0.34$5K129K
May 17, 2024Buy(P)22K$0.68$15K116K

Transaction Codes

A
Grant / award
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-25-005698) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML